跳至主要内容
临床试验/CTRI/2021/04/032795
CTRI/2021/04/032795尚未招募4 期

Role of High Flow Nasal Cannula (HFNC) as a treatment modality in patients with hypoxemic respiratory failure due to COVID - 19

Government Medical College Vadodara0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • COVID â?? 19 pneumonia (Diagnosed with polymerase chain reaction)
  • Age more than 18 years of either gender
  • Acute Hypoxemic Respiratory Failure
  • Admission to intensive care unit
  • Supported by high flow nasal cannulae

排除标准

  • Intubation prior to HFNC therapy
  • Uncooperative and neurologically (Glasgow coma scale less than equal to 12) unstable patients
  • Patients with haemodynamic instability
  • Patients with primary pulmonary disease, respiratory acidosis in the first blood gases (pH < 7.2,pCO2 >= 50)
  • In all conditions where PEEP is contraindicated like in presence of pneumothorax, large bullae in lungs or haemodynamic instability.
  • Patient not accepting nasal cannula due to irritation or discomfort

研究者

发起方
Government Medical College Vadodara

相似试验